Savara (SVRA) Change in Accured Expenses (2010 - 2026)
Savara (SVRA) reported Change in Accured Expenses of -$4.6 million for Q1 2026, down 47.24% year-over-year from -$8.8 million in Q1 2025, and down 227.09% on a QoQ basis from $3.6 million in Q4 2025.
Savara (SVRA) has 17 years of Change in Accured Expenses data on file, last reported at -$4.6 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 47.24% year-over-year to -$4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (up 82.06% YoY) and the FY2025 annual result came in at $4.8 million, up 14.4% from the prior year.
- Change in Accured Expenses declined to -$4.6 million in Q1 2026 per SVRA's latest filing, from $3.6 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.6 million in Q4 2025 and bottomed at -$4.6 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is $1.2 million (2025), against an average of $505529.4.
- The widest annual swing landed in 2023, when Change in Accured Expenses jumped 6075.0%; it then slumped 308.83% in 2025.
- Tracing SVRA's Change in Accured Expenses over 5 years: stood at $445000.0 in 2022, then soared by 230.34% to $1.5 million in 2023, then jumped by 53.74% to $2.3 million in 2024, then jumped by 61.37% to $3.6 million in 2025, then sank by 227.09% to -$4.6 million in 2026.
- Per Business Quant, the three latest SVRA Change in Accured Expenses figures stand at -$4.6 million (Q1 2026), $3.6 million (Q4 2025), and $3.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | -4.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.64 Mn |
| Mar 31, 2026 | -4.64 Mn |
| Dec 31, 2025 | 3.65 Mn |
| Dec 31, 2025 | 3.65 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | -770,000.00 |
| Mar 31, 2024 | -770,000.00 |
| Dec 31, 2023 | 1.47 Mn |
| Dec 31, 2023 | 1.47 Mn |
| Sep 30, 2023 | 3.06 Mn |
| Sep 30, 2023 | 3.06 Mn |
| Jun 30, 2023 | 988,000.00 |
| Jun 30, 2023 | 988,000.00 |
| Mar 31, 2023 | -976,000.00 |
| Mar 31, 2023 | -976,000.00 |
| Dec 31, 2022 | 445,000.00 |
| Dec 31, 2022 | 445,000.00 |
| Sep 30, 2022 | 1.70 Mn |
| Sep 30, 2022 | 1.70 Mn |
| Jun 30, 2022 | 16,000.00 |
| Jun 30, 2022 | 16,000.00 |
| Mar 31, 2022 | -2.48 Mn |
| Mar 31, 2022 | -2.48 Mn |
| Dec 31, 2021 | -278,000.00 |
| Dec 31, 2021 | -278,000.00 |
| Sep 30, 2021 | 928,000.00 |
| Sep 30, 2021 | 928,000.00 |
| Jun 30, 2021 | -1.63 Mn |
| Jun 30, 2021 | -1.63 Mn |
| Mar 31, 2021 | -781,000.00 |
| Mar 31, 2021 | -781,000.00 |
| Dec 31, 2020 | 70,000.00 |
| Dec 31, 2020 | 70,000.00 |
| Sep 30, 2020 | 1.17 Mn |
| Sep 30, 2020 | 1.17 Mn |
| Jun 30, 2020 | 804,000.00 |
| Jun 30, 2020 | 804,000.00 |
| Mar 31, 2020 | -3.18 Mn |
| Mar 31, 2020 | -3.18 Mn |
| Dec 31, 2019 | 139,000.00 |
| Dec 31, 2019 | 139,000.00 |
| Sep 30, 2019 | -712,000.00 |
| Sep 30, 2019 | -712,000.00 |
| Jun 30, 2019 | 188,000.00 |
| Jun 30, 2019 | 188,000.00 |
| Mar 31, 2019 | 953,000.00 |
| Mar 31, 2019 | 953,000.00 |
| Dec 31, 2018 | 155,000.00 |
| Dec 31, 2018 | 155,000.00 |
| Sep 30, 2018 | 1.84 Mn |
| Sep 30, 2018 | 1.84 Mn |
| Jun 30, 2018 | 110,000.00 |
| Jun 30, 2018 | 110,000.00 |
| Mar 31, 2018 | -554,000.00 |
| Mar 31, 2018 | -554,000.00 |
| Dec 31, 2017 | -10,000.00 |
| Dec 31, 2017 | -10,000.00 |
| Sep 30, 2017 | -1.70 Mn |
| Sep 30, 2017 | -1.70 Mn |
| Jun 30, 2017 | 528,000.00 |
| Jun 30, 2017 | 528,000.00 |
| Mar 31, 2017 | 1.32 Mn |
| Mar 31, 2017 | 1.32 Mn |
| Dec 31, 2016 | 1.01 Mn |
| Dec 31, 2016 | 1.01 Mn |
| Sep 30, 2016 | 533,000.00 |
| Sep 30, 2016 | 533,000.00 |
| Jun 30, 2016 | 591,000.00 |
| Jun 30, 2016 | 591,000.00 |
| Mar 31, 2016 | -358,000.00 |
| Mar 31, 2016 | -358,000.00 |
| Dec 31, 2015 | -3.74 Mn |
| Dec 31, 2015 | -3.74 Mn |
| Sep 30, 2015 | 1.17 Mn |
| Sep 30, 2015 | 1.17 Mn |
| Jun 30, 2015 | 1.63 Mn |
| Jun 30, 2015 | 1.63 Mn |
| Mar 31, 2015 | 733,000.00 |
| Mar 31, 2015 | 733,000.00 |
| Dec 31, 2014 | 467,000.00 |
| Dec 31, 2014 | 467,000.00 |
| Sep 30, 2014 | 1.81 Mn |
| Sep 30, 2014 | 1.81 Mn |
| Jun 30, 2014 | -139,000.00 |
| Jun 30, 2014 | -139,000.00 |
| Mar 31, 2014 | -62,000.00 |
| Mar 31, 2014 | -62,000.00 |
| Dec 31, 2013 | 973,364.00 |
| Dec 31, 2013 | 973,364.00 |
| Sep 30, 2013 | 910,068.00 |
| Sep 30, 2013 | 910,068.00 |
| Jun 30, 2013 | 60,129.00 |
| Jun 30, 2013 | 60,129.00 |
| Mar 31, 2013 | 563,439.00 |
| Mar 31, 2013 | 563,439.00 |
| Dec 31, 2012 | -7,016.00 |
| Dec 31, 2012 | -7,016.00 |
| Sep 30, 2012 | 80,874.00 |
| Sep 30, 2012 | 80,874.00 |
| Jun 30, 2012 | 580,102.00 |
| Jun 30, 2012 | 580,102.00 |
| Mar 31, 2012 | -533,492.00 |
| Mar 31, 2012 | -533,492.00 |
| Dec 31, 2011 | -155,101.00 |
| Dec 31, 2011 | -155,101.00 |
| Sep 30, 2011 | 90,576.00 |
| Sep 30, 2011 | 90,576.00 |
| Jun 30, 2011 | -71,010.00 |
| Jun 30, 2011 | -71,010.00 |
| Mar 31, 2011 | 332,061.00 |
| Mar 31, 2011 | 332,061.00 |
| Dec 31, 2010 | 725,105.00 |
| Dec 31, 2010 | 725,105.00 |
| Sep 30, 2010 | -251,501.00 |
| Sep 30, 2010 | -251,501.00 |